Dipexium Pharmaceuticals, Inc. (PLXP)
(Delayed Data from NSDQ)
$5.62 USD
+0.20 (3.76%)
Updated May 3, 2019 04:13 PM ET
After-Market: $5.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.62 USD
+0.20 (3.76%)
Updated May 3, 2019 04:13 PM ET
After-Market: $5.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 15.91% and 35.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 9.53% and 0.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Baudax Bio, Inc. (BXRX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of -366.04% and 75.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PLx Pharma, Inc. (PLXP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 7.14% and 86.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 4.35% and 11.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Dipexium Pharmaceuticals, Inc. (PLXP) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dipexium Pharmaceuticals, Inc. (PLXP) delivered earnings and revenue surprises of -5.80% and 17.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Dipexium Pharmaceuticals (PLXP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Dipexium Pharmaceuticals (PLXP) stock based on the movements in the options market lately.
Is a Surprise Coming for PLx Pharma (PLXP) This Earnings Season?
by Zacks Equity Research
PLx Pharma (PLXP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
New Analyst Coverage Puts Spotlight on These 4 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Guess' (GES), Babcock (BW), Wabash (WNC) and PLx Pharma (PLXP).
Earnings Preview: PLx Pharma (PLXP) Q2 Earnings Expected to Decline
by Zacks Equity Research
PLx Pharma (PLXP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLx Pharma (PLXP) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
PLx Pharma (PLXP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.